TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04026815

Intervention type: OTHER
Intervention: medical history, blood and urine tests
Description: The study protocol consists of questionnaires (medical, socio-economic, dietary), comprehensive geriatric assessment, physical examination, anthropometric and blood pressure measurements and laboratory tests.

Intervention type: OTHER
Intervention: medical history, blood and urine tests
Description: The study protocol consists of questionnaires (medical, socio-economic, dietary), comprehensive geriatric assessment, physical examination, anthropometric and blood pressure measurements and laboratory tests.

Intervention type: OTHER
Intervention: medical history, blood and urine tests
Description: The study protocol consists of questionnaires (medical, socio-economic, dietary), comprehensive geriatric assessment, physical examination, anthropometric and blood pressure measurements and laboratory tests.

Intervention type: OTHER
Intervention: medical history, blood and urine tests
Description: The study protocol consists of questionnaires (medical, socio-economic, dietary), comprehensive geriatric assessment, physical examination, anthropometric and blood pressure measurements and laboratory tests.

Intervention type: OTHER
Intervention: medical history, blood and urine tests
Description: The study protocol consists of questionnaires (medical, socio-economic, dietary), comprehensive geriatric assessment, physical examination, anthropometric and blood pressure measurements and laboratory tests.

Intervention type: OTHER
Intervention: medical history, blood and urine tests
Description: The study protocol consists of questionnaires (medical, socio-economic, dietary), comprehensive geriatric assessment, physical examination, anthropometric and blood pressure measurements and laboratory tests.

Intervention type: OTHER
Intervention: medical history, blood and urine tests
Description: The study protocol consists of questionnaires (medical, socio-economic, dietary), comprehensive geriatric assessment, physical examination, anthropometric and blood pressure measurements and laboratory tests.
Study: NCT04275895

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Evaluation of different attention or/and postural activities
Description: 1. The children, equipped with a head-mounted display (HMD), will indicate as quickly as possible the direction of a fish that can be surrounded by congruent or not flankers (Inhibition) and/or preceded by signal (Alert)~2. The children, equipped with a HMD and a joystick, will vertically turn a randomly inclined stick~3. The children will stand on a force plate watching a cartoon, gazing a fixation cross or eyes closed~4. The children, equipped with an augmented reality headset, will perform 2 levels of difficulty of 3 attention tasks standing on a force plate:~   * They will click as quickly as possible when they see a frog among successively appearing animals (vigilance task)~  * They will give the name of an animal appearing at one of the windows displayed (visual search task)~  * They will count the number of yellow lions oriented to the right among several animals of different color and direction (inhibition task)~5. Growth trajectory will be retrieved from health booklet

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Evaluation of different attention or/and postural activities
Description: 1. The children, equipped with a head-mounted display (HMD), will indicate as quickly as possible the direction of a fish that can be surrounded by congruent or not flankers (Inhibition) and/or preceded by signal (Alert)~2. The children, equipped with a HMD and a joystick, will vertically turn a randomly inclined stick~3. The children will stand on a force plate watching a cartoon, gazing a fixation cross or eyes closed~4. The children, equipped with an augmented reality headset, will perform 2 levels of difficulty of 3 attention tasks standing on a force plate:~   * They will click as quickly as possible when they see a frog among successively appearing animals (vigilance task)~  * They will give the name of an animal appearing at one of the windows displayed (visual search task)~  * They will count the number of yellow lions oriented to the right among several animals of different color and direction (inhibition task)~5. Growth trajectory will be retrieved from health booklet
Study: NCT01050556

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: daily, 24 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: folic acid
Description: 400 ug/d for 12 or 24 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: folic acid
Description: 800 µg/d for 12 or 24 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: creatine
Description: 3 mg/d for 12 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: creatine + folic acid
Description: 3 mg creatine/d + 400 µg folic acid/d for 12 weeks
Study: NCT00633672

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esomeprazole
Description: 20mg Oral tablet once daily
Study: NCT03816670

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Corifollitropin Alfa
Description: late start (day 4) vs. corifollitropin-alfa standard start (day 2)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Corifollitropin Alfa
Description: late start (day 4) vs. corifollitropin-alfa standard start (day 2)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Corifollitropin Alfa
Description: late start (day 4) vs. corifollitropin-alfa standard start (day 2)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Corifollitropin Alfa
Description: late start (day 4) vs. corifollitropin-alfa standard start (day 2)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Corifollitropin Alfa
Description: late start (day 4) vs. corifollitropin-alfa standard start (day 2)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Corifollitropin Alfa
Description: late start (day 4) vs. corifollitropin-alfa standard start (day 2)
Study: NCT03252340

Intervention type: DRUG
Intervention: ADSTEM Inj.
Description: 1. ADSTEM Inj. 1.0x10\^8 mesenchymal stem cells as an intravenous infusion once in Phase I clinical trial.~2. ADSTEM Inj. 3.0x10\^8 mesenchymal stem cells as an intravenous infusion once in Phase I clinical trial.
Study: NCT01985854

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Desflurane
Study: NCT03603509

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluad Vaccine
Description: FLUAD is an inactivated influenza vaccine indicated for active immunization against influenza. disease caused by influenza virus subtypes A and type B contained in the vaccine. FLUAD is. approved for use in persons 65 years of age and older.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluzone High-Dose
Description: FLUZONE® HIGH-DOSE vaccine is indicated for people 65 years of age and older to help prevent influenza disease caused by influenza A and B strains contained in the vaccine.
Study: NCT02574572

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous mesenchymal cells transplantation
Description: All patients will undergo laminectomy and autologous mesenchymal cells injection into the lesion area.
Study: NCT01097876

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04447943 25 mg
Description: 25 mg PF-04447943 BID for 7 days (period 1) 7 day washout (no drug) 7 days of 5 mg donepezil QD; 14 days 10 mg QD (Period 2) 7 days of 10 mg donepezil QD and 25 mg PF-04447943 BID (Period 3)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo PF
Description: Placebo BID for 7 days (period 1) 7 day washout (no drug) 7 days of 5 mg donepezil QD; 14 days 10 mg QD (Period 2) 7 days of 10 mg donepezil QD and Placebo BID (Period 3)
Study: NCT00633672

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ranitidine
Description: 150mg oral twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esomeprazole
Description: 40mg oral tablet once daily
Study: NCT02853019

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Electroencephalogram
Description: electrophysiological measurements (evoked potentials) based on neural activity when visualizing stimuli

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electroencephalogram
Description: electrophysiological measurements (evoked potentials) based on neural activity when visualizing stimuli

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Cognitive tasks
Description: - clinical scales and subjective assessments of emotional and motivational stimuli

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive tasks
Description: - clinical scales and subjective assessments of emotional and motivational stimuli
Study: NCT04438070

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: COVID-19 Swab
Description: Nasal, Oral-Nasal combined or Nasopharyngeal swab
Study: NCT02676622

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Preparative regimen 4-6 weeks after Leukapheresis
Description: Prior to starting medicines, a central venous line will be placed (arm or chest)~Cyclophosphamide iv: 50 mg/kg iv over 2 hours~Mesna iv (uro-protectant): 36 mg/kg iv over 12 hours~r-ATG (Thymoglobulin, Genzyme): 2.5 mg/kg/dose iv over 6 hours on days -3,-2,-1

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Stem Cell Transplant
Description: Infusion of the(cryopreserved and thawed)peripheral blood stem cells (PBSC)occurs on Day 0.~Day +5: start Filgrastim (G-csf) subcutaneous injections~Hospitalization in isolation room for 4-5 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low-dose IL-2 administration
Description: IL-2 Subcutaneous injections will start once ANC is \> 500/µL and patient is afebrile (start IL-2 will be approximately day +20)for 6 weeks of treatment.~Once patient or parent has learnt the administration and patient is tolerating it well, then the rest of the treatment can be administered at home after discharge with weekly follow up visits.
Study: NCT02944825

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ciprofloxacin
Description: first line prophylactic oral antibiotic

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: trimethoprim/sulfamethoxazole
Description: second line prophylactic oral antibiotic

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: No Intervention
Description: No intervention
Study: NCT04607785

Intervention type: DRUG
Group type: OTHER
Intervention: Miswak mouthwash group
Description: Twice daily for seven days for two months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Miswak mouthwash group
Description: Twice daily for seven days for two months

Intervention type: DEVICE
Group type: OTHER
Intervention: Chlorhexidine gluconate mouthwash
Description: Twice daily for seven days for two months

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Chlorhexidine gluconate mouthwash
Description: Twice daily for seven days for two months
Study: NCT02569905

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: parecoxib sodium
Description: parecoxib sodium 40mg
Study: NCT04438070

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: COVID-19 Swab
Description: Nasal, Oral-Nasal combined or Nasopharyngeal swab

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: COVID-19 Swab
Description: Nasal, Oral-Nasal combined or Nasopharyngeal swab

Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: COVID-19 Swab
Description: Nasal, Oral-Nasal combined or Nasopharyngeal swab
Study: NCT03272789

Intervention type: OTHER
Group type: OTHER
Intervention: Interviews with coach
Description: For Interviews : done at Day 0 and at 1, 2, 3, 6 and 12 months. Questionnaires : given at Day 0, and at 3, 6 and 12 months.
Study: NCT02569905

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: flurbiprofen
Description: flurbiprofen 50mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: saline
Description: normal saline
Study: NCT01733888

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Office Bleaching
Description: Teeth will be cleaned with pumice first, followed by placing cheek retractors and covering of the lip surface with petroleum gel. Thereafter, teeth will be dried and gingival barrier will be applied to both arches - slightly overlapping enamel and interproximal spaces. Light curing of the gingival barrier will be done in a fanning motion for 10-20 seconds. This is followed by homogeneous mixing of the powder and liquid in a powder pot the application of a thick layer of the resulting gel to all teeth undergoing treatment (35 % Hydrogen Peroxide, Pola Office, SDI, Australia). The gel will be left in place for 8 minutes and subsequently removed using a surgical aspirator tip.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Resin Infiltration
Description: Fluorosed teeth will be isolated using a rubber dam and the resin infiltrant (Icon, DMG, Hamburg, Germany) will be applied as per manufactures' instructions. In short, tooth surface will be dried using cotton rolls and air syringe. This is followed by an etching (Icon Etch) and drying step (Icon-Dry) to open the lesion surface. Resin infiltrant will then be applied and allowed to seep in for 3 minutes followed by light curing for 40 seconds and subsequent cleaning of the surface with pumice and rubber polishing cup as well as rinsing with water for 30 sec.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Resin Infiltration twice
Description: The intervention will be done similar to the Resin infiltration arm, which the exception that the icon infiltration step will be done twice.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bleaching + Resin Infiltration
Description: In this arm, the fluorosed teeth of the patients will first be bleached using 35 % Hydrogen Peroxide (Pola Office, SDI, Australia) as explained in the intervention arm Office bleaching; followed by wash over period of 20 days. After these 20 days, patients will be recalled and the fluorosed teeth will treated according to the description in the Resin infiltrant intervention arm using the resin infiltrant (Icon, DMG, Hamburg, Germany) as per manufactures' instructions.
Study: NCT01326936

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online education
Description: A brief (2-hour) interactive online training program in substance abuse (SU) management using virtual patient (VP) technology. Each learner will take one of two similar online programs involving five VPs that represent the range of SU management issues that commonly arise in clinical practice.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online education
Description: A brief (2-hour) interactive online training program in substance abuse (SU) management using virtual patient (VP) technology. Each learner will take one of two similar online programs involving five VPs that represent the range of SU management issues that commonly arise in clinical practice.
Study: NCT01000038

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Wii-Fit intervention
Description: Half hour daily, 5 days a week for 8 weeks

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Walking
Description: Half hour daily, five days a week for 8 weeks

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Walking
Description: Half hour daily, five days a week for 8 weeks
Study: NCT04172064

Intervention type: DIAGNOSTIC_TEST
Intervention: Myocardial perfusion scintigraphy
Study: NCT01752712

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CBSST + Oxytocin
Description: The oxytocin dose of 80 IU/day, will be administered in two divided doses: 40 IU in the morning and 40 IU in the evening. Oxytocin will be administered intranasally (10 puffs of the spray, 5 in each nostril at each administration). CBSST groups will occur for an hour twice/week. Nasal spray will be administered an hour prior to the CBSST group.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: CBSST + Placebo
Description: Matching placebo spray will be administered intranasally (10 puffs of the spray, 5 in each nostril at each administration). CBSST groups will occur for an hour twice/week. Nasal spray will be administered an hour prior to the CBSST group.
Study: NCT03127800

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Morphine sulphate
Description: 5mg of intravenous morphine sulphate diluted to 5ml with normal saline (0.9% sodium chloride) will be administered 30 minutes before participant's bed time. The same dose will be administered four hours later. In both instances 4 mg of intravenous ondansetron will be administered after the morphine sulphate dose to prevent sickness.
Study: NCT00375869

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Darbeopoetin
Description: The treatment group, comprised of ten patients, will receive an intravenous dose of 200 mcg (1 ml) of darbepoetin (Aranesp®). Patients will be randomly assigned to either the treatment group, or the control group in a 2:1 ratio. The treatment group will be given 200 mcg of darbepoetin intravenously. The control group will be given a matching placebo of 1 mL of normal saline.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline (Placebo)
Description: The treatment group, comprised of ten patients, will receive an intravenous dose of 200 mcg (1 ml) of darbepoetin (Aranesp®). Patients will be randomly assigned to either the treatment group, or the control group in a 2:1 ratio. The treatment group will be given 200 mcg of darbepoetin intravenously. The control group will be given a matching placebo of 1 mL of normal saline.
Study: NCT01850433

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Internet based CBT for body dysmorphic disorder
Study: NCT01794169

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DA
Study: NCT03008330

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: High-activity natural killer
Description: Each treatment: 8-10 billion cells in all, transfuion in 3 times, i.v.
Study: NCT00353015

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin 25 mg/m2 IV days 1, 8 of a 21-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: Irinotecan 65 mg/m2 IV days 1, 8 of a 21-day cycle
Study: NCT00358579

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adrenaline
Description: 1 mg
Study: NCT00697580

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nutrition
Description: Nutrition classes for 1 hour \& 30 minutes once a week for 16 weeks + motivational interviewing (4 individual sessions)
Study: NCT00358579

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vasopressin
Description: 40 IU
Study: NCT02402231

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omalizumab
Description: Omalizumab is the treatment during oral immunotherapy with peanuts as protection
Study: NCT01925820

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegasys&Entecavir
Description: 180 mcg Peg-IFN alfa-2a (Pegasys) once a week for 48 weeks. Entecavir daily will also be administered concurrently for 48 weeks and then given as monotherapy for an additional 96 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pegasys&Entecavir
Description: 180 mcg Peg-IFN alfa-2a (Pegasys) once a week for 48 weeks. Entecavir daily will also be administered concurrently for 48 weeks and then given as monotherapy for an additional 96 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pegasys&Entecavir
Description: 180 mcg Peg-IFN alfa-2a (Pegasys) once a week for 48 weeks. Entecavir daily will also be administered concurrently for 48 weeks and then given as monotherapy for an additional 96 weeks.
Study: NCT00697580

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Strength Training & Nutrition
Description: Strength Training twice a week for 1 hour a day for 16 weeks + Nutrition once a week for 1 hour \& 30 minutes for 16 weeks + motivational interviewing (4 individual \& 4 group sessions)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Circuit Training & Nutrition
Description: Circuit Training twice a week for 1 hour a day for 16 weeks + Nutrition once a week for 1 hour \& 30 minutes for 16 weeks + motivational interviewing (4 individual \& 4 group sessions)
Study: NCT04358601

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Triathlon PS Knee System with all-polyethylene tibial components
Description: Primary Total Knee Replacement

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Triathlon PS Knee System with metal-backed modular components
Description: Primary Total Knee Replacement
Study: NCT01283243

Intervention type: DEVICE
Intervention: Acoustic radiation force impulse imaging
Description: Acoustic radiation force impulse (ARFI) imaging were measured 10 times in each patient.The region of interest was chosen in an area where the normal liver parenchyma was at least 6 cm thick and free of large blood vessels was chosen. A measurement depth of 2 cm below the liver capsule was chosen to standardize the examination.
Study: NCT01283854

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Supervised home-based exercise
Description: Each participant randomised to the exercise group will be required to participate in three 60-minute exercise sessions each week, starting at 14 weeks gestation, for a total of 14 weeks (i.e. to be completed by 28 weeks of gestation). All exercise sessions will be home-based and fully supervised by an experienced exercise physiologist. The exercise program will be implemented in accordance with the American College of Sports Medicine and the American College of Obstetrics and Gynecology guidelines. All sessions will be conducted on a stationary cycle ergometer.~Heart rate will be measured continuously during exercise to ensure that the exercise intensity is maintained as prescribed. In addition, blood pressure and rate of perceived exertion will be monitored at 10-min intervals. Perceived exertion will not be allowed to exceed a rating of 14 (i.e. somewhat hard).
Study: NCT03081078

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Volunteer support
Description: Each participant will be matched with a pair of trained volunteers (under pre-determined safety measures), who will initiate caring contact via telephone or text messages at least twice a month for two months. Participants will be free to respond or not.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mobile app
Description: Participants will receive programmed care messages and reminders of community resources and healthcare contacts on a regular basis. The app will also provide simple self-help mood checking and relaxation exercises.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mobile app
Description: Participants will receive programmed care messages and reminders of community resources and healthcare contacts on a regular basis. The app will also provide simple self-help mood checking and relaxation exercises.